Application of thermophilic Streptococcus STN26 bacterial agent in the preparation of products for preventing or / and improving constipation associated with Parkinson's disease
The STN26 bacteria agent for Streptococcus thermophilus STN26 has improved the moisture content of feces and regulated related components, which has solved the side effects of constipation in Parkinson's disease, significantly improved the symptoms of Parkinson's disease with constipation, and provided a more effective treatment plan.
Patent Information
- Application Number
- CN202411124419.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-08-16
AI Technical Summary
The prior art methods to improve Parkinson's disease with constipation have side effects and are difficult to effectively solve the constipation problem in patients with Parkinson's disease.
Using Streptococcus thermophilus STN26 bacteria agent, the Streptococcus thermophilus STN26 bacteria agent was prepared by culturing in MRS liquid culture medium and lyophilized with isomaltose, and then mixed with oligomeric isomaltose was used to improve feces. Water content, regulates the content of SCF protein, c-kit protein, acetylcholinesterase, nitric oxide and short-chain fatty acids, and improves constipation symptoms.
It significantly improves the happiness of patients with Parkinson's disease and constipation. By increasing the moisture content of feces and reducing gastric content residues, it prevents constipation and regulates relevant components after constipation occurs, significantly improves constipation symptoms, which is more effective than other bacterial agents. To be effective.
Smart Images

Figure CN118634253B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of microorganisms, and in particular to application of a thermophilic streptococcus STN26 bacterial agent in preparing a product for preventing or / and improving constipation associated with Parkinson's disease. Background Art
[0002] Parkinson's disease is a dopaminergic neurodegenerative movement disorder characterized by damage and loss of dopaminergic neurons in the substantia nigra of the brain, which causes movement-related disorders, including uncontrollable muscle tremors, hunchback, bradykinesia, and difficulty moving. With the in-depth study of Parkinson's disease, some researchers have proposed the intestinal origin theory of Parkinson's disease, that is, symptoms in the intestines precede those in the brain, and dysphagia, constipation, and irritable bowel syndrome can significantly increase the risk of Parkinson's disease. Patients with these symptoms are more likely to be diagnosed with Parkinson's disease many years later. In addition, most Parkinson's patients are also accompanied by constipation. In some tissue sample tests, it has been pointed out that the intestines of Parkinson's patients will show symptoms up to 20 years before the brain.
[0003] There are many ways to improve constipation associated with Parkinson's disease, such as (1) adjusting lifestyle habits: drink more honey water, exercise more, eat more fruits and vegetables rich in dietary fiber, and develop the habit of regular bowel movements every day, but adjusting work and rest is only an auxiliary means and requires long-term persistence to see significant results. (2) Taking medicine: The medicines that relieve constipation associated with Parkinson's disease are mainly laxatives. Laxatives with Chinese patent medicine ingredients generally contain irritating ingredients such as senna leaves and rhubarb, which can irritate the colon and cause colon melanosis. Long-term use can easily induce colon cancer; osmotic laxatives, mainly containing lactulose and mannitol, are prone to electrolyte disorders and should be used with caution for elderly people or Parkinson's patients with renal insufficiency; lubricating oil laxatives, such as paraffin oil, should be used with caution for Parkinson's patients who are bedridden for a long time to avoid aspiration pneumonia; gastrointestinal motility drugs, mainly mosapride and prucalopride, are prone to cause side effects such as headaches, nausea, and vomiting. (3) Acupuncture: Acupuncture can help improve constipation in Parkinson's patients, but it can cause skin damage to patients, aggravate their physical and mental pain, and make it difficult to persist. Summary of the invention
[0004] In view of the technical problem that conventional medical means in the prior art have more or less side effects in improving constipation associated with Parkinson's disease, the present invention provides the use of a thermophilic Streptococcus STN26 bacterial agent in the preparation of a product for preventing and / or improving constipation associated with Parkinson's disease.
[0005] The technical solution of the present invention is as follows:
[0006] Application of thermophilic Streptococcus STN26 bacterial agent in the preparation of products for preventing or / and improving constipation associated with Parkinson's disease, thermophilic Streptococcus ( Streptococcus thermophilus ) STN26 was inoculated into MRS liquid culture medium, the bacteria were collected by centrifugation, washed, and resuspended in reconstituted skim milk. After freeze-drying, it was mixed with oligomaltose to obtain the thermophilic Streptococcus STN26 bacterial agent for improving constipation associated with Parkinson's disease; Streptococcus thermophilus STN26 was deposited in the General Microbiology Center of China National Culture Collection Administration on May 27, 2021, with the deposit address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC NO.22618; the finished product is a medicine.
[0007] Furthermore, the number of bacteria in the thermophilic Streptococcus STN26 bacterial agent is 10 billion / g.
[0008] Further, symptoms of Parkinson's disease include less movement, slower movements, hunched back, and a tendency to lean to one side when moving forward.
[0009] Furthermore, constipation prevention includes increasing the water content of stool and reducing gastric residual contents.
[0010] Furthermore, improving constipation includes increasing SCF protein content and c-kit protein content.
[0011] Further, improving constipation involves regulating neurotransmitters.
[0012] Further, modulation of neurotransmitters includes increasing acetylcholine hydrolase levels and decreasing nitric oxide levels.
[0013] Further, improving constipation includes regulating short-chain fatty acids.
[0014] Further, regulating the short-chain fatty acids includes increasing the content of acetate, propionate and butyrate.
[0015] The beneficial effects of the present invention are:
[0016] The thermophilic streptococcus STN26 agent provided by the present invention can prevent the occurrence of constipation by increasing the water content of feces and reducing the residual gastric contents before the occurrence of constipation associated with Parkinson's disease; after the occurrence of constipation associated with Parkinson's disease, the symptoms of constipation can be significantly improved by regulating the contents of SCF protein, c-kit protein, acetylcholinesterase, nitric oxide, acetic acid, propionic acid and butyric acid, thereby improving the sense of well-being of patients with Parkinson's disease and constipation. Compared with the thermophilic streptococcus agent of comparative example 1 and the bifidobacterium lactobacillus triple live bacteria tablets claiming to have the effect of improving constipation, the thermophilic streptococcus STN26 agent provided by the present invention has an outstanding effect in improving the constipation associated with Parkinson's disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.
[0018] Figure 1 It is the protein blotting image of STN26 group, blank group and model group in Experimental Example 2. DETAILED DESCRIPTION
[0019] In order to enable those skilled in the art to better understand the technical solutions in the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.
[0020] Example 1 Screening of strains that promote acetylcholinesterase (AchE) activity
[0021] Neurotransmitters are chemical substances secreted by nerve cells to regulate intestinal motility. Once the secretion is unbalanced, it can cause intestinal dysfunction and increase the risk of constipation. Among them, acetylcholine (Ach) is an excitatory intestinal motility neurotransmitter that can stimulate intestinal muscle contraction and promote intestinal peristalsis. AchE is the hydrolase of Ach.
[0022] (1) Preparation of MRS liquid medium and MRS plate medium
[0023] MRS liquid culture medium includes 10g of peptone, 5g of beef powder, 5g of sodium acetate trihydrate, 2g of dipotassium hydrogen phosphate heptahydrate, 1mL of Tween 80, 0.05g of manganese sulfate tetrahydrate, 2g of triammonium citrate, 20g of glucose, 0.2g of magnesium sulfate heptahydrate, and 1000mL of distilled water; after mixing the above raw materials, adjusting the pH to 6.8, stirring evenly, and sterilizing at 121°C and 0.1MPa for 20min to obtain MRS liquid culture medium;
[0024] The MRS plate culture medium includes 10 g of peptone, 5 g of beef powder, 5 g of sodium acetate trihydrate, 2 g of potassium hydrogen phosphate heptahydrate, 1 mL of Tween 80, 0.05 g of manganese sulfate tetrahydrate, 2 g of triammonium citrate, 20 g of glucose, 0.2 g of magnesium sulfate heptahydrate, 15 g of agar, and 1000 mL of distilled water. The above raw materials are mixed, the pH is adjusted naturally, the mixture is stirred evenly, and the mixture is sterilized at 121° C. and 0.1 MPa for 20 min, poured into a plate, and cooled to obtain the MRS plate culture medium.
[0025] (2) Sample preparation
[0026] The five strains of thermophilic Streptococcus STN26 and lactic acid bacteria A31-03, lactic acid bacteria X1-01, lactic acid bacteria X47-01, and lactic acid bacteria X62-01 stored in the applicant's strain library were selected and activated on MRS plate culture medium. The five activated strains were inoculated into MRS liquid culture medium at 1.0 Vol% inoculation amount, cultured at 37 ° C for 24 hours, placed in a sterilizing pot at 115 ° C for 30 minutes to prepare an inactivated bacterial solution, and 125 μL of the inactivated bacterial solution of each strain was mixed with 100 μL of acetylcholinesterase solution, placed on ice, and five samples to be tested were obtained. Among them, the concentration of the acetylcholinesterase solution is 1U, and the solvent is phosphate buffer.
[0027] (3) Detection and screening of strains that promote acetylcholinesterase activity
[0028] The acetylcholinesterase kit (manufacturer: Wuhan Saipei Biotechnology Co., Ltd.) was used to detect the samples according to the instructions. Three parallel groups were set up for each sample to be tested. The average value of the relative enzyme activity was taken. The initial enzyme activity of the acetylcholinesterase solution was taken as 100% to represent the relative enzyme activity of the sample to be tested. The results are shown in Table 1.
[0029] Table 1 Relative enzyme activities of the samples tested
[0030]
[0031] As shown in Table 1, among the five strains, Streptococcus thermophilus STN26 had the highest relative enzyme activity and stronger activity in promoting acetylcholinesterase, so Streptococcus thermophilus STN26 was selected for subsequent experiments.
[0032] Example 2 Preparation of Streptococcus thermophilus STN26 bacterial agent
[0033] The preserved thermophilic Streptococcus STN26 was activated on an MRS plate medium (the formula and preparation method are shown in Example 1), and the activated thermophilic Streptococcus STN26 was inoculated into an MRS liquid medium (the formula and preparation method are shown in Example 1) at an inoculum amount of 1.0 Vol%, and cultured at 37° C. for 24 h, and then the cells were collected by centrifugation, washed with sterile saline, and resuspended in 15% (w / w) reconstituted skim milk (manufacturer: Henan Huaxing Biotechnology Co., Ltd.) to obtain a suspension; the concentration of the suspension was adjusted to 1.0-2.0×10 10 cfu / mL, a bacterial suspension was obtained, and after freeze-drying the bacterial suspension, a thermophilic Streptococcus STN26 bacterial powder was obtained. The thermophilic Streptococcus STN26 bacterial powder was mixed with oligomalto-oligosaccharide (manufacturer: Bowling Biotechnology Co., Ltd.) to prepare a thermophilic Streptococcus STN26 bacterial agent.
[0034] The number of bacteria of Streptococcus thermophilus STN26 inoculant was 10 billion / g as detected by plate counting method.
[0035] Comparative Example 1
[0036] The thermophilic Streptococcus lyophilized powder (Article No.: HZB142509, Manufacturer: Wuhan Huizao Biotechnology Co., Ltd.) was dissolved in MRS liquid culture medium (formula and preparation method see Example 1), and the dissolved thermophilic Streptococcus lyophilized powder was activated on MRS plate culture medium (formula and preparation method see Example 1), and the activated thermophilic Streptococcus was inoculated into MRS liquid culture medium at a rate of 1.0 Vol%, and cultured at 37° C. for 24 h, and then the cells were collected by centrifugation, washed with sterile saline, and resuspended in 15% (w / w) reconstituted skim milk (Manufacturer: Henan Huaxing Biotechnology Co., Ltd.) to obtain a suspension; the concentration of the suspension was adjusted to 1.0-2.0×10 10 cfu / mL, a bacterial suspension was obtained, and the bacterial suspension was freeze-dried to obtain thermophilic Streptococcus powder, which was mixed with isomaltooligosaccharide (manufacturer: Bowling Biotechnology Co., Ltd.) to prepare a thermophilic Streptococcus agent.
[0037] The number of thermophilic streptococci detected by plate count method was 10 billion / g.
[0038] Comparative Example 2
[0039] Bifidobacterium and Lactobacillus triple live bacteria tablets (manufacturer: Inner Mongolia Shuangqi Pharmaceutical Co., Ltd.).
[0040] The instructions state that each gram of Bifidobacterium-Lactobacillus Triple Live Bacteria Tablet contains 1.0×10 Bifidobacterium longum. 7 cfu, Lactobacillus bulgaricus not less than 1.0×10 6 cfu, Streptococcus thermophilus not less than 1.0×10 6 cfu.
[0041] Experimental Example 1 Experiment on the prevention of constipation in rats with Parkinson's disease and constipation by using Streptococcus thermophilus STN26 bacterial agent
[0042] 1. Construction of rat model of Parkinson's disease with constipation
[0043] 1.1 Grouping
[0044] Fifty SPF-grade healthy SD male rats weighing (230±20) g were purchased from Jinan Pengyue Experimental Animal Breeding Co., Ltd. and were fed adaptively for 1 week. The feeding conditions were: sufficient food and water, temperature of 25°C, 12h bright and 12h dark. After 1 week of adaptation, the rats were randomly divided into 5 groups for drug administration, with 10 rats in each group, including model group, STN26 group, blank group, control group 1 and control group 2.
[0045] 1.2 Administration
[0046] The rats in the STN26 group were gavaged with Streptococcus thermophilus STN26 inoculated with saline (8 million cfu / day per rat) at a final concentration of 5×10 7 cfu / mL; compared with the thermophilic Streptococcus powder prepared in Comparative Example 1 dissolved in physiological saline (added at 8 million cfu / day per rat), the final concentration was 5×10 7 cfu / mL; two groups of rats were compared by gavage with 3.8g of Bifidobacterium-Lactobacillus triple live bacteria tablets mixed with normal saline (Comparative Example 2), and the amount of normal saline was the same as that of the STN26 group; the rats in the blank group and the model group were gavaged with the same volume of normal saline and fed continuously for 14 days.
[0047] 1.3 Modeling
[0048] Rotenone powder (manufacturer: Sigma) was dissolved in sunflower oil solvent to prepare a rotenone suspension with a concentration of 2 mg / mL (prepared and used immediately, stored at room temperature and away from light), and injected subcutaneously into the back of the neck of rats in the model group, STN26 group, control group 1 and control group 2 at a dose of 2 mg / kg, once a day for 28 consecutive days, to establish a rat model of Parkinson's disease with constipation.
[0049] 2. Behavioral evaluation of Parkinson's disease with constipation model
[0050] 2.1 Detection of successful Parkinson's disease modeling
[0051] APO-induced climbing experiment: Animal experimental climbing cages were used. 5 min before the start of the experiment, rats in the model group, STN26 group, blank group, control group 1 and control group 2 were placed in cages to adapt to the environment. Apomorphine (APO, manufacturer: Sigma) was injected subcutaneously and then put back into the cages. The injection volume was 0.75 mg / kg. The climbing behavior of the rats was observed and scored one by one. The scoring criteria are shown in Table 2. Each group was tested 3 times, with an interval of 10 min each time. The values of the 3 tests for each rat were recorded and the average was taken for data analysis.
[0052] Table 2 Scoring criteria
[0053]
[0054] The experimental data obtained were expressed as ±S. SPSS 26.0 was used to analyze the data. When the comparisons among multiple groups met the normal distribution and variance homogeneity, one-way ANOVA analysis was used. P < 0.05 was considered to be statistically significant.
[0055] Table 3 The climbing behavior scores of rats in each group
[0056]
[0057] Note: * It indicates that P<0.05 compared with the blank group among the STN26 group, model group, comparison group 1, comparison group 2.
[0058] After 28 days of modeling, rats in the STN26 group, model group, comparison group 1 and comparison group 2 all showed yellow, frizzy and dirty hair, hunched back, less movement, slow movement, and body leaning to one side when moving forward, which preliminarily determined that the Parkinson's disease model was successful. As shown in Table 3, compared with the blank group, the scores of the STN26 group, model group, comparison group 1 and comparison group 2 were significantly reduced (P < 0.05), which further verified that the Parkinson's disease model was successfully established in rats in the STN26 group, model group, comparison group 1 and comparison group 2.
[0059] 2.2 Detection of successful constipation modeling and detection of the effect of thermophilic Streptococcus STN26 on preventing constipation in rats with Parkinson's disease and constipation
[0060] The rats in the Parkinson's disease model group, STN26 group, blank group, control group 1 and control group 2 were tested for constipation model by fecal water content and gastric content residual rate.
[0061] 2.2.1 Detection of feces moisture content
[0062] The rats in the Parkinson's disease model group, STN26 group, blank group, control group 1 and control group 2 were separated, each of which was raised individually and fed a normal diet. The feces of each rat were collected and weighed in units of 1 hour. After collecting for 24 hours, the feces weight of each group of rats was calculated and recorded as the wet weight of feces; the feces were heated in a drying oven at 150°C for 25 minutes and then weighed, and then heated for another 5 minutes and weighed again. The drying operation was repeated until the feces weight no longer changed. The weight of the dried feces was recorded as the dry weight of feces, and the feces moisture content was calculated. The results are shown in Table 4.
[0063]
[0064] The experimental data obtained were expressed as ±S. SPSS 26.0 was used to analyze the data. When the comparisons among multiple groups met the normal distribution and variance homogeneity, one-way ANOVA analysis was used. P < 0.05 was considered to be statistically significant.
[0065] Table 4 Water content of feces of rats in each group
[0066]
[0067] Note: * indicates that P < 0.05 compared with the blank group; # Indicates P < 0.05 compared with the model group in the STN26 group, the comparison group 1, and the comparison group 2; @ It indicates that P<0.05 compared with the blank group in the STN26 group, the control group 1, the control group 2.
[0068] As shown in Table 4, the fecal moisture content of the model group was significantly lower than that of the blank group (P < 0.05), indicating that the constipation model was successfully established. The fecal moisture content of the STN26 group was not significantly different from that of the blank group, indicating that the thermophilic Streptococcus STN26 bacterial agent can prevent constipation associated with Parkinson's disease. The fecal moisture content of the comparison group 1 and the comparison group 2 was significantly different from that of the blank group (P < 0.05), indicating that the thermophilic Streptococcus bacterial agent of the comparative example 1 and the bifidobacterium and lactobacillus triple live bacteria tablets of the comparative example 2 had no effect on preventing constipation associated with Parkinson's disease.
[0069] 2.2.2 Detection of gastric content residual rate
[0070] Preparation of activated carbon solution: Take a beaker and add 50g of gum arabic and 400mL of distilled water. Bring to a boil and simmer over low heat until the solution is transparent. After filtering out impurities, add 25g of activated carbon. Boil the solution 3 times, then bottle it after it cools down for later use.
[0071] The rats in the Parkinson's disease model group, STN26 group, control group 1, control group 2 and blank group were fasted but not watered. After 24 hours, they were allowed to eat freely for 1 hour, and the food was removed. The food consumption before and after eating was calculated. After an interval of 30 minutes, the rats were gavaged with activated carbon solution. After 21 hours, the rats were anesthetized and killed, and the stomach was taken and wiped dry with filter paper, weighed and recorded. Then the stomach was cut open and rinsed with physiological saline, and then wiped dry with filter paper after washing, and the net weight of the stomach was weighed to calculate the residual rate of stomach contents. The results are shown in Table 5.
[0072]
[0073] The experimental data obtained were expressed as ±S. SPSS 26.0 was used to analyze the data. When the comparisons among multiple groups met the normal distribution and variance homogeneity, one-way ANOVA analysis was used. P < 0.05 was considered to be statistically significant.
[0074] Table 5 Gastric content residual rate of rats in each group
[0075]
[0076] Note: * indicates that P < 0.05 compared with the blank group; # Indicates P < 0.05 compared with the model group in the STN26 group, the comparison group 1, and the comparison group 2; @ It indicates that P<0.05 compared with the blank group in the STN26 group, the control group 1, the control group 2.
[0077] As shown in Table 5, the residual rate of gastric contents in the model group was significantly higher than that in the blank group (P < 0.05), indicating that the constipation model was successfully established. The residual rate of gastric contents in the STN26 group was not significantly different from that in the blank group, indicating that thermophilic streptococcus STN26 can prevent constipation associated with Parkinson's disease. The residual rates of gastric contents in the comparison group 1 and the comparison group 2 were significantly different from those in the blank group (P < 0.05), indicating that the thermophilic streptococcus agent in comparative example 1 and the bifidobacterium and lactobacillus triple live bacteria tablets in comparative example 2 had no effect on preventing constipation associated with Parkinson's disease.
[0078] Experimental Example 2 Experiment on the effect of Streptococcus thermophilus STN26 on the expression of SCF protein and c-kit protein in colon tissue of rats with Parkinson's disease and constipation
[0079] The construction of the rat model of Parkinson's disease with constipation in Experimental Example 1 was carried out in the order of 1.1 grouping, 1.3 modeling and 1.2 drug administration (that is, the drug administration before modeling in Experimental Example 1 was changed to drug administration after modeling, and the research on preventing constipation associated with Parkinson's disease was changed to research on improving constipation associated with Parkinson's disease). Specifically, after modeling according to the method of 1.3, 2.1 detection of successful Parkinson's disease modeling and 2.2.1 detection of fecal water content were carried out. After confirming that the modeling was successful, the blank group, model group, STN26 group, comparison group 1 and comparison group 2 rats were subjected to the operation of 1.2 drug administration.
[0080] After the administration, the rats in the blank group, model group, STN26 group, control group 1, and control group 2 were fasted but not watered for 12 h, and anesthetized with 0.4% pentobarbital at a dose of 1 mL / g by intraperitoneal injection and placed on an ice tray. The rats were fixed with transparent medical tape on their heads and limbs in a supine position, and about 1 mL of blood was drawn from the heart with an EP tube. The rats were killed by cervical dislocation, and 2 cm of the middle colon tissue of the rats in each group was obtained, rinsed, put into a cryovial, and quickly frozen in liquid nitrogen. After 15 min, they were transferred to a -80 °C refrigerator for storage in preparation for subsequent protein detection.
[0081] Western Blot radioimmunoassay was used to detect the levels of SCF protein and c-kit protein in colon tissue. The specific steps are as follows:
[0082] (1) Sample preparation: complete lysis, centrifugation after lysis to obtain the supernatant, protein quantification and storage after freezing; (2) Protein quantification; (3) Preparation of the lower separation gel and the upper concentration gel; (4) Sample loading and electrophoresis; (5) Transfer to membrane; (6) Detection of proteins on the membrane: Wash the membrane once in TBST, then place it in the Ponceau red staining working solution, shake and stain at room temperature for 5 minutes, wash the membrane with water until the water becomes clear and the colorless protein bands are clear. The PVDF membrane needs to be reactivated with methanol (it must be activated before transfer to the membrane), then washed with TBST and sealed. Blocking; (7) Blocking and antibody incubation of membrane, blocking: 5% skim milk powder blocking at room temperature for 1 hour or 4°C overnight; primary antibody: dilute the antibody, add the antibody to the blocking solution and dilute to the required concentration, and incubate with the membrane at room temperature for 2 hours or 4°C overnight; secondary antibody: the membrane incubated with the primary antibody is washed with TBST, and then the HRP-labeled secondary antibody is diluted at 1:1000 according to the dosage, and incubated with the membrane at 37°C for 1 hour; wash with TBST; (8) color development: ECL chemiluminescence detection, put it into the imaging system for scanning; (9) Use Image J software to compare the gray value, and the ratio of the gray value of the band to the gray value of the internal reference α-tubulin is the basis for relative quantitative analysis. The results are shown in the figure below. Figure 1 , as shown in Table 6.
[0083] Microsoft Excel 2021 was used to process the database, and then SPSS 26.0 was used for statistical processing. The experimental results were expressed as mean ± standard deviation. One-way ANOVA was used for inter-group comparisons, and the least significant difference (LSD) method was used for pairwise comparisons between groups. P < 0.05 indicated statistical significance.
[0084] Table 6 Detection results of SCF protein and c-kit protein in each group
[0085]
[0086] Note: *It means P<0.05 compared with the model group and the blank group; # Indicates P < 0.05 compared with the model group in the STN26 group, the comparison group 1, and the comparison group 2; @ It indicates that P<0.05 compared with the blank group in the STN26 group, the control group 1, the control group 2.
[0087] As shown in Table 6, there were significant differences in the relative expression of SCF protein and c-kit protein in the colon tissue of the model group rats compared with the blank group (P < 0.05), indicating that the constipation model was successfully established. There was no significant difference in the relative expression of SCF protein and c-kit protein in the colon tissue of the STN26 group rats compared with the blank group (P < 0.05), and there was a significant difference in the relative expression of SCF protein and c-kit protein in the colon tissue of the STN26 group rats compared with the model group (P < 0.05), indicating that the thermophilic Streptococcus STN26 bacterial agent can increase the content of SCF protein and c-kit protein in the colon tissue, which can further illustrate that thermophilic Streptococcus STN26 has an alleviating effect on constipation associated with Parkinson's disease rats. Figure 1 It can be seen that the relative expression levels of SCF protein and c-kit protein in the colon tissue of rats in the STN26 group are not much different from those in the blank group.
[0088] The relative expression of SCF protein and -kit protein in the colon tissue of rats in group 1 was significantly different from that in the blank group (P < 0.05), but not significantly different from that in the model group (P < 0.05), indicating that the thermophilic Streptococcus used in group 1 had no effect on improving constipation associated with Parkinson's disease. The relative expression of SCF protein and c-kit protein in the colon tissue of rats in group 2 was significantly different from that in the blank group (P < 0.05), but not significantly different from that in the model group (P < 0.05), indicating that the bifidobacterium-lactobacillus triple live bacteria tablets used in group 2 had no obvious effect on improving constipation associated with Parkinson's disease and could not reach the normal level.
[0089] Experimental Example 3: Experiment on the regulation of NO and AchE in rats with Parkinson's disease and constipation by Streptococcus thermophilus STN26
[0090] Nitric oxide and acetylcholine are important intestinal neurotransmitters. Unlike acetylcholine, nitric oxide is an inhibitory intestinal motility neurotransmitter, which has a strong effect of relaxing intestinal smooth muscle and blood vessels, inhibiting intestinal tension and relaxing intestinal muscles.
[0091] Blood was collected from the hearts of the rats in the blank group, model group, STN26 group, control group 1 and control group 2 in Experimental Example 2 after anesthesia. The blood was allowed to stand at room temperature for 20-30 minutes until coagulation, and then centrifuged at low temperature for 10 minutes (4°C, 3000rpm / min). The supernatant was aspirated with a pipette and placed in a -80°C refrigerator for testing.
[0092] The levels of NO and AchE in the serum of rats in each group were detected by double antibody sandwich method using ELISA kit (manufacturer: Wuhan Saipei Biotechnology Co., Ltd.).
[0093] The experimental data obtained were expressed as ±S. SPSS 26.0 was used to analyze the data. When the comparisons among multiple groups met the normal distribution and variance homogeneity, one-way ANOVA analysis was used. P < 0.05 was considered to be statistically significant.
[0094] Table 7 NO and AchE detection results of each group
[0095]
[0096] Note: * It means P<0.05 compared with the model group and the blank group; # Indicates P < 0.05 compared with the model group in the STN26 group, the comparison group 1, and the comparison group 2; @ It indicates that P<0.05 compared with the blank group in the STN26 group, the control group 1, the control group 2.
[0097] As shown in Table 7, there were significant differences in the NO and AchE contents in the serum of the model group rats compared with those in the blank group (P < 0.05), indicating that the constipation model was successfully established. The NO and AchE contents in the serum of the STN26 group rats were significantly different from those in the model group (P < 0.05). It can be seen that the increased NO content and decreased AchE content in the model group significantly inhibited the defecation of the rats. The NO and AchE contents in the serum of the STN26 group rats were not significantly different from those in the blank group (P < 0.05), indicating that the thermophilic Streptococcus STN26 bacterial agent can promote defecation by reducing the NO content and increasing the AchE content in Parkinson's disease rats, and has a relieving effect on the constipation associated with Parkinson's disease.
[0098] The NO and AchE contents in the serum of rats in group 1 were significantly different from those in the blank group (P < 0.05), but not significantly different from those in the model group (P < 0.05), indicating that the thermophilic streptococcus used in group 1 had no effect on improving constipation associated with Parkinson's disease. The NO and AchE contents in the serum of group 2 were significantly different from those in the blank group (P < 0.05), but not significantly different from those in the model group (P < 0.05), indicating that the bifidobacterium-lactobacillus triple live bacteria tablets used in group 2 had no obvious effect on improving constipation associated with Parkinson's disease and could not reach the normal level.
[0099] Experimental Example 4 Effect of Streptococcus thermophilus STN26 on fecal short-chain fatty acid content in rats with Parkinson's disease and constipation
[0100] Intestinal microorganisms can convert complex nutrients such as plant cell wall components such as cellulose, pectin, lignin and mucin into monosaccharides, which are then fermented to form short-chain fatty acids, mainly including acetic acid, propionic acid, butyric acid, etc., which can provide energy for host cells and participate in regulating the host intestinal flora, promote defecation by regulating signal pathways, improve intestinal motility, and relieve constipation.
[0101] The short-chain fatty acid content of the rats killed by cervical dislocation in Experimental Example 2 was detected. The feces from the distal colon to the upper part of the anal canal of the rats were carefully squeezed out from the distal end of the colon, placed in a labeled cryotube, and stored in a -80°C ultra-low temperature refrigerator. The short-chain fatty acid content was detected by gas chromatography-mass spectrometry (GC-MS).
[0102] Chromatographic conditions: The samples were separated using an Agilent DB-WAX capillary column (30m×0.25mmID×0.25um) gas chromatography system. Program temperature rise: initial temperature 90°C; temperature rise to 120°C at 10°C / min; temperature rise to 150°C at 5°C / min, and finally temperature rise to 250°C at 25°C / min and maintained for 2 minutes. The carrier gas was helium with a flow rate of 1.0mL / min. A QC sample was set every certain number of experimental samples in the sample queue to detect and evaluate the stability and repeatability of the system.
[0103] Mass spectrometry analysis: Agilent 7890A / 5975C gas-mass spectrometer was used for mass spectrometry analysis. Inlet temperature was 250°C; ion source temperature was 230°C; transfer line temperature was 250°C, and quadrupole temperature was 150°C. Electron impact ionization (EI) source, full scan and SIM scanning mode, electron energy 70eV. MSD Chem Station software was used to extract chromatographic peak area and retention time. A standard curve was drawn to calculate the content of short-chain fatty acids in the sample. The results are shown in Table 8.
[0104] The experimental data obtained were expressed as ±S. SPSS 26.0 was used to analyze the data. When the comparisons among multiple groups met the normal distribution and variance homogeneity, one-way ANOVA analysis was used. P < 0.05 was considered to be statistically significant.
[0105] Table 8 Contents of acetic acid, propionic acid and butyric acid in each group
[0106]
[0107] Note: * It means P<0.05 compared with the model group and the blank group; # Indicates P < 0.05 compared with the model group in the STN26 group, the comparison group 1, and the comparison group 2; @It indicates that P<0.05 compared with the blank group in the STN26 group, the control group 1, the control group 2.
[0108] As shown in Table 8, the fecal short-chain fatty acid content of the model group rats was significantly different from that of the blank group (P < 0.05), indicating that the model was successfully established. The fecal short-chain fatty acid content of the STN26 group rats was significantly different from that of the model group (P < 0.05), but not significantly different from that of the blank group (P < 0.05), indicating that the thermophilic Streptococcus STN26 bacterial agent can promote defecation by increasing the intestinal short-chain fatty acid content of high Parkinson's disease rats, and has a certain effect on relieving constipation associated with Parkinson's disease.
[0109] The fecal short-chain fatty acid content of rats in group 1 was significantly different from that of the blank group (P < 0.05), but not significantly different from that of the model group (P < 0.05), indicating that the thermophilic streptococcus used in group 1 had no effect on improving constipation associated with Parkinson's disease. The fecal short-chain fatty acid content of rats in group 2 was significantly different from that of the blank group (P < 0.05), but not significantly different from that of the model group (P < 0.05), indicating that the bifidobacterium-lactobacillus triple live bacteria tablets used in group 2 had no obvious effect on improving constipation associated with Parkinson's disease and could not reach the normal level.
[0110] Although the present invention has been described in detail with reference to the accompanying drawings and in combination with the preferred embodiments, the present invention is not limited thereto. Without departing from the spirit and essence of the present invention, a person of ordinary skill in the art may make various equivalent modifications or substitutions to the embodiments of the present invention, and these modifications or substitutions shall be within the scope of the present invention. Any person of ordinary skill in the art may easily think of changes or substitutions within the technical scope disclosed by the present invention, and these shall be within the scope of protection of the present invention.
Claims
1. Use of a thermophilic Streptococcus STN26 bacterial agent in the preparation of a product for preventing and / or improving constipation associated with Parkinson's disease, characterized in that: Streptococcus thermophilus STN26 is inoculated into MRS liquid culture medium, the bacteria are collected by centrifugation, washed, and resuspended in reconstituted skim milk. After freeze-drying, it is mixed with oligomaltose to obtain a Streptococcus thermophilus STN26 bacterial agent for improving constipation associated with Parkinson's disease; the preservation number of Streptococcus thermophilus STN26 is CGMCCNO.22618; the product is a medicine; improving constipation includes increasing the SCF protein content and c-kit protein content.
2. The use according to claim 1, characterized in that The number of bacteria in the thermophilic Streptococcus STN26 bacterial agent is 10 billion / g.
3. The use according to claim 1, characterized in that Symptoms of Parkinson's disease include less movement, slower movements, a hunched back, and a tendency to lean to one side when moving forward.
4. The use according to claim 1, characterized in that Preventing constipation includes increasing the water content of stool and reducing gastric residual contents.
5. The use according to claim 1, characterized in that Improving constipation involves regulating neurotransmitters.
6. The use according to claim 5, characterized in that Modulation of neurotransmitters includes increasing acetylcholine hydrolase levels and decreasing nitric oxide levels.
7. The use according to claim 1, characterized in that Improving constipation involves regulating short-chain fatty acids.
8. The use according to claim 7, characterized in that Modulating short-chain fatty acids includes increasing the levels of acetate, propionate and butyrate.
Citation Information
Patent Citations
Microbial preparation with inactivated bacteria MN002 as well as preparation method and application of microbial preparation
CN113201469A
Streptococcus thermophilus STN26, bacterial powder and application of streptococcus thermophilus STN26 in uric acid reducing products
CN113249280A
